MBX Biosciences, Inc./$MBX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MBX Biosciences, Inc.
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.
Ticker
$MBX
Sector
Primary listing
Employees
43
Headquarters
Website
MBX Metrics
BasicAdvanced
$484M
-
-$2.88
-
-
Price and volume
Market cap
$484M
52-week high
$15.94
52-week low
$4.81
Average daily volume
428K
Financial strength
Current ratio
19.496
Quick ratio
19.203
Long term debt to equity
0.234
Total debt to equity
0.296
Profitability
EBITDA (TTM)
-86.285
Management effectiveness
Return on assets (TTM)
-36.75%
Return on equity (TTM)
-56.28%
Valuation
Price to book
2.21
Price to tangible book (TTM)
2.21
Price to free cash flow (TTM)
-5.371
Free cash flow yield (TTM)
-18.62%
Free cash flow per share (TTM)
-2.681
Growth
Earnings per share change (TTM)
-92.85%
Bulls say / Bears say
Maintained a strong cash position with $224.9 million in cash, cash equivalents and marketable securities as of June 30, 2025, providing funding into mid-2027 (Globe Newswire)
Advancing a diverse pipeline with major milestones approaching: Phase 2 topline results for canvuparatide (MBX 2109) expected in Q3 2025, Phase 2a initiation for imapextide (MBX 1416) in Q3 2025, and Phase 1 initiation for MBX 4291 in Q3 2025 (Globe Newswire)
Phase 2 Avail™ trial of canvuparatide (MBX 2109) completed enrollment with 64 patients, surpassing original targets and setting the stage for top-line results in Q3 2025 (Globe Newswire)
Net loss increased to $23.9 million in Q1 2025, nearly doubling from $12.3 million a year ago, signaling a faster rate of cash burn (GuruFocus News)
Research and development expenses rose sharply to $22.4 million in Q1 2025, up from $11.0 million in Q1 2024, reflecting higher costs as multiple programs progress (GuruFocus News)
Cash balance dropped by $15.9 million from $240.8 million on March 31, 2025, to $224.9 million on June 30, 2025, indicating that spending could exceed expectations if the pipeline grows further (Globe Newswire/Globe Newswire)
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MBX Biosciences, Inc. stock?
MBX Biosciences, Inc. (MBX) has a market cap of $484M as of September 04, 2025.
What is the P/E ratio for MBX Biosciences, Inc. stock?
The price to earnings (P/E) ratio for MBX Biosciences, Inc. (MBX) stock is 0 as of September 04, 2025.
Does MBX Biosciences, Inc. stock pay dividends?
No, MBX Biosciences, Inc. (MBX) stock does not pay dividends to its shareholders as of September 04, 2025.
When is the next MBX Biosciences, Inc. dividend payment date?
MBX Biosciences, Inc. (MBX) stock does not pay dividends to its shareholders.
What is the beta indicator for MBX Biosciences, Inc.?
MBX Biosciences, Inc. (MBX) does not currently have a Beta indicator.